Journal Mobile Options
Table of Contents
Vol. 109, No. 1, 2008
Issue release date: June 2008

Association of High-Molecular-Weight to Total Adiponectin Ratio with Pulse Wave Velocity in Hemodialysis Patients

Kato A. · Odamaki M. · Ishida J. · Hishida A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

High-molecular-weight adiponectin (HMW ADPN) plays an important role in the regulation of insulin action and atherogenic processes, but the role of HMW ADPN remains to be determined in hemodialysis (HD) patients. In this study, we measured serum total and HMW ADPN in 67 HD patients (age: 67 ± 14 years, time on HD: 75 ± 68 months, male/female = 39/28), and examined an association between HMW ADPN and arteriosclerotic parameters such as aortic pulse wave velocity (PWV), cardio-ankle vascular index (CAVI) and ankle-brachial pressure index (ABI). PWV was significantly correlated positively with log-transformed IL-6 (r = 0.33, p < 0.01). CAVI was significantly related to the percentile of aortic calcification area (%ACA) (r = 0.28, p = 0.03) and log-transformed IL-6 (r = 0.25, p = 0.05). ABI was associated negatively with log-transformed IL-6 (r = –0.35, p < 0.01) and %ACA (r = –0.36, p < 0.01), but positively with albumin (r = 0.33, p < 0.01). The HMW-to-total ADPN ratio, a better predictor for insulin resistance, was significantly and positively correlated with PWV (r = 0.34, p < 0.01) and CAVI (r = 0.24, p = 0.05). A multiple stepwise regression analysis revealed that the HMW-to-total ADPN ratio was an independent determinant for PWV and CAVI but not for ABI. The findings suggest that HMW-to-total ADPN ratio may be positively associated with aortic stiffness in HD patients.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439–451.
  2. Kobayashi H, Ouchi N, Kihara S, et al: Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e27–e31.
  3. Bodles AM, Banga A, Rasouli N, et al: Pioglitazone increases secretion of high-molecular weight adiponectin from adipocytes. Am J Physiol 2006;292:E1100–E1105.
  4. Nakashima R, Kamei N, Yamane K, et al: Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 2006;91:3873–3877.
  5. Hara K, Horikoshi M, Yamauchi T, et al: Measurement of the high molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006;29:1357–1362.
  6. Katsuki A, Suematsu M, Gabazza EC, et al: Decreased high molecular weight adiponectin-to-total adiponectin ratio in sera is associated with insulin resistance in Japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Care 2006;29:2327–2328.
  7. Komaba H, Igaki N, Goto S, et al: Increased serum high-molecular weight complex of adiponectin in type 2 diabetic patients with impaired renal function. Am J Nephrol 2006;26:476–482.
  8. Shen YY, Charlesworth JA, Kelly JJ, et al: Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 2007;22:171–178.
  9. Shen YY, Charlesworth JA, Kelly JJ, Peake PW: The effect of renal transplantation on adiponectin and its isoforms and receptors. Metabolism 2007;56:1201–1208.
  10. Okura T, Watanabe S, Kurata M, et al: Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. Hypertens Res 2007;30:335–340.
  11. Odamaki M, Furuya R, Kinumura Y, et al: Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients. Nephron 2006;102:c8–c13.
  12. Odamaki M, Shibata T, Takita T, Kumagai H: Serum fetuin-A and aortic calcification in hemodialysis patients. Kidney Int 2005;68:2916.

    External Resources

  13. Yambe T, Yoshizawa M, Saijo Y, et al: Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother 2004;58(suppl 1):S95–S98.
  14. Shirai K, Utino J, Otsuka K, Takata M: A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006;13:101–107.
  15. Araki T, Emoto M, Yokoyama H, et al: The association of plasma adiponectin level with carotid arterial stiffness. Metabolism 2006;55:587–592.
  16. Mahmud A, Feely J: Adiponectin and arterial stiffness. Am J Hypertens 2005;18:1543–1548.
  17. Aso Y, Yamamoto R, Wakabayashi S, et al: Comparison of serum high molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using an oval enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006;55:1954–1960.
  18. Inoue T, Kotooka N, Morooka T, et al: High molecular adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 2007;100:569–574.
  19. Zoccali C, Mallamaci F, Tripepi G, et al: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134–141.
  20. Becker B, Kronenberg F, Kielstein JT, et al: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: The Mild and Moderate Kidney Disease Study. J Am Soc Nephrol 2005;16:1091–1098.
  21. Iwashima Y, Horio T, Kumada M, et al: Adiponectin and renal function, and implications as a risk of cardiovascular disease. Am J Cardiol 2006;98:1603–1608.
  22. Diez JJ, Iglesias P, Fernandez-Reyes MJ, et al: Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol 2005;62:242–249.
  23. Ignacy W, Chudek J, Adamczak M, et al: Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease – a follow-up study. Nephron Clin Pract 2005;101:c18–c24.
  24. Kistrop C, Faber J, Galatius S, et al: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756–1762.
  25. Schalkwijk CG, Chaturvedi N, Schram MT, et al: Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 2006;91:129–135.
  26. Wannamethee SG, Whincup PH, Lennon L, Sattar N: Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007;167:1510–1517.
  27. Kollerits B, Fliser D, Heid IM, et al: Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: The Mild to Moderate Kidney Disease Study. Kidney Int 2007;71:1279–1286.
  28. Ohashi N, Kato A, Misaki T, et al: Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med 2008;47:485–491.
  29. McEntegart MB, Awede B, Petrie MC, et al: Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007;28:829–835.
  30. Malyszko J, Malyszko JS, Brzosko S, et al: Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab 2004;89:4620–4627.
  31. Fésüs G, Dubrovska G, Gorzelniak K, et al: Adiponectin is a novel humoral vasodilator. Cardiovasc Res 2007;75:719–727.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50